Gastroenterology in September 2026: SPY003 phase 2 data in UC, antifungal therapy in IBD, and EPI prevalence in chronic pancreatitis.
News|Videos|April 8, 2026
Q1 2026 Recap: Gastroenterology News and Updates
Author(s)Abigail Brooks, MA
Fact checked by: Victoria Johnson
Q1 2026 GI updates include advances in IBD and IBS therapies, long-term data, and new insights into access challenges for younger patients.
Advertisement
Advertisement
The first quarter of 2026 delivered a steady stream of meaningful updates in gastroenterology, with advances spanning irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and real-world insights into treatment access and durability. Across clinical trials and observational research, the field continues to move toward more personalized, evidence-driven care while also grappling with persistent gaps in access and affordability.
Related to this article
Strong recommendations cover carvedilol or banding for varices, semiannual HCC surveillance, vaccines, and smoking cessation.
Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.
Remibrutinib doubled complete Total Fric Score response vs placebo at week 12 in RemIND, becoming the first therapy approved specifically for SD.
Presented at EASD 2026, the present analysis discusses CBL-514’s apparent efficacy in reducing L2-L3 visceral fat compared to placebo.
A hepatologist on the lag between drinking and liver disease, metabolic risk, prevention gaps, and when the burden may peak.
Nephrology in Q3 2026: FDA approvals for atacicept, iptacopan, finerenone, and obinutuzumab, plus 2-year IgAN data and CKD screening.
Q3 2026 dermatology recap: FDA approvals in dermatomyositis, adolescent alopecia areata, and sBCC, plus new psoriasis and vitiligo findings.
Advertisement
Advertisement